【レポートの概要（一部）】
1. Report Overview
1.1 Multiple Sclerosis Drugs Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Multiple Sclerosis
2.1 What is Multiple Sclerosis?
2.1.1 Key Statistics: 2.5 Million Sufferers in the World
2.2 The Pathology of MS
2.2.1 Symptoms
2.3 Diagnosis of MS
2.3.1 Tests for MS Include These Technologies
2.4 Measuring MS
2.5 The Different Types of MS
2.5.1 Relapsing-Remitting MS (RRMS)
2.5.2 Secondary Progressive MS
2.5.3 Progressive Relapsing MS
2.5.4 Primary Progressive MS
2.5.5 Other Presentations of the Disease
2.6 Possible Causational Factors for MS
2.6.1 Genetic Factors
2.6.2 Infection
2.6.3 Environmental Factors and Less Well-Supported Theories
2.7 Demographics and Geographical Distribution
2.8 Different Treatments for MS
3. Leading Multiple Sclerosis Drugs
3.1 Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
3.1.1 First Non-Interferon Immunomodulator
3.1.2 Teva and the Approval of Generic Competition
3.1.3 The First Generic is Approved – Sandoz’s Glatopa
3.1.4 Industry Surprised by Copaxone’s Solid Sales, Despite Generic Competition: 40mg Dose is Key
3.1.5 Patents on Copaxone 40mg Being Contested – Although Teva Receives Good News in Europe
3.1.6 Copaxone Revenues 2011-2015
3.1.7 Copaxone Revenue Forecast 2016-2026
3.2 Tecfidera (dimethyl fumarate) by Biogen
3.2.1 Rapidly Grown Since 2013 to Become the Leading Oral MS Therapy
3.2.2 Tecfidera Revenues 2013-2015
3.2.3 Tecfidera Revenue Forecast 2016-2026
3.3 Avonex (interferon beta-1a) by Biogen
3.3.1 The Leading Interferon Therapy
3.3.2 Avonex Revenues 2011-2015
3.3.3 Patent Extension to 2026
3.3.4 Avonex Revenue Forecast 2016-2026
3.4 Gilenya (fingolimod) by Novartis
3.4.1 The First Oral Disease-Modifying Drug for MS
3.4.2 US Patent Trial and Appeal Board Sides Against Novartis
3.4.3 Gilenya Revenues 2011-2015
3.4.4 Gilenya Revenue Forecast 2016-2026
3.5 Rebif (interferon beta-1a) by Merck KGaA
3.5.1 Merck Attempting to Differentiate Rebif from Other Interferon Therapies
3.5.2 Rebif Revenues 2011-2015
3.5.3 Rebif Revenue Forecast 2016-2026
3.6 Tysabri (natalizumab) by Biogen
3.6.1 High Efficacy Offsets the Risks
3.6.2 Tysabri Revenues 2011-2015
3.6.3 Tysabri Revenue Forecast 2016-2026
3.7 Betaseron / Betaferon (interferon beta-1b) by Bayer
3.7.1 First Disease Modifying Drug for MS
3.7.2 Betaseron Revenues 2011-2015
3.7.3 Betaseron Revenue Forecast 2016-2026
3.8 Aubagio (teriflunomide) by Sanofi
3.8.1 More than 48,000 Patients Treated
3.8.2 Aubagio Revenues 2014-Q1 2016
3.8.3 Aubagio Revenue Forecast 2016-2026
3.9 Plegridy (peginterferon beta-1a) by Biogen
3.9.1 36% Reduction in ARR compared to Placebo
3.9.2 Plegridy Revenues 2014-2015
3.9.3 Plegridy Revenue Forecast 2016-2026
3.10 Lemtrada (alemtuzumab) by Sanofi
3.10.1 Very Effective, but with Side Effects
3.10.2 Lemtrada Past Revenues and Revenue Forecast 2016-2026
4. Multiple Sclerosis Drugs Pipeline 2016-2026
4.1 Ocrelizumab (Ocrevus / RG1594) by Roche
4.1.1 Humanised mAb Targeting CD20
4.1.2 First Drug to Receive Breakthrough Therapy Designation for MS
4.1.3 Exciting Latest Results from Two Phase 3 Trials
4.1.4 Ongoing Clinical Trials
4.1.5 Ocrelizumab Revenue Forecast 2016-2026
4.2 Ozanimod by Celgene
4.2.1 S1PR Modulator
4.2.2 Promising Results from Phase 2 RADIANCE Study
4.2.3 Ongoing Clinical Trials
4.2.4 Ozanimod in MS Revenue Forecast 2018-2026
4.3 Zinbryta (daclizumab high-yield process) by Biogen and AbbVie
4.3.1 Humanised mAb Being Jointly Developed by two Giants
4.3.2 Positive Opinion on Marketing Authorisation from the CHMP
4.3.3 Zinbryta Revenue Forecast 2016-2026
4.4 Ofatumumab by Novartis
4.4.1 Novartis Acquires Full Remaining Rights in $1bn Agreement
4.4.2 Advantages and Disadvantages over Ocrelizumab
4.5 Ponesimod by Actelion
4.5.1 S1PR Modulator
4.5.2 Positive Earlier Results
4.6 Laquinimod by Teva and Active Biotech
4.6.1 Troubled Oral Immunomodulator
4.6.2 Turned Down for European Licence
4.7 MED1003 by MedDay
4.7.1 Unique Method of Action
4.7.2 Results from MS-SPI and MS-ON
4.8 Masitinib by AB Science: Phase 3 and has Completed a Futility Analysis
4.9 Siponimod (BAF312) by Novartis: Competitor for Gilenya
5. Global Multiple Sclerosis Drugs Market 2016-2026
5.1 Global Multiple Sclerosis Drugs Market Forecast 2016-2026
5.2 What Factors Will Drive Growth in the Global MS Drugs Market?
5.2.1 Growth of Existing Products, Reaching Peak Blockbuster Revenues before Patent Expiry
5.2.2 Exciting New Products Due to be Launched Within the Next Ten Years
5.2.3 Premium Prices, Accompanied by Price Increases
5.2.4 Prevalence and Incidence of Multiple Sclerosis is Increasing
5.2.5 Unmet Needs and Strategic Partnering
5.3 What Factors will Restrain Growth in the Global MS Drugs Market?
5.3.1 Multiple Patent Expiries on Leading Drugs will Lead to Generic and Biosimilar Competition
5.3.2 Declining Healthcare Budgets Could Lead to Cost Pressures
5.3.3 Crowded Marketplace
6. Leading Therapeutic Segments: Revenue Prospects, 2016-2026
6.1 The Main Therapeutic Segments within the MS Drugs Market, Forecast 2016-2026
6.2 Therapeutic Composition of the Market in 2015, 2020 and 2026
6.3 Monoclonal Antibodies Segment Forecast 2016-2026
6.4 S1PR Modulator Segment Forecast 2016-2026
6.5 Interferons Segment Forecast 2016-2026
6.6 Other Immunomodulators Segment Forecast 2016-2026
6.7 ‘Others’ Segment Forecast 2016-2026
7. National Markets for MS Drugs: Revenue Prospects, 2016-2026
7.1 Multiple Sclerosis Cases and Prevalence Values
7.2 Leading Regional Markets Forecast 2016-2026
7.2.1 Regional Composition of the Market in 2015, 2020 and 2026
7.3 US MS Drugs Market
7.3.1 Reasons why the US Market Dominates the MS Drugs Market to Such an Extent
7.3.2 Undergoing Some Changes
7.3.3 US MS Drugs Market Forecast 2016-2026
7.4 EU5 MS Drugs Market 2016-2026
7.4.1 Common Characteristics of all the EU5 Nations in Regards to MS Drugs and Drivers of Growth
7.4.2 German MS Drugs Market: Leading EU Market
7.4.2.1 German MS Drugs Market Forecast 2016-2026
7.4.3 French MS Drugs Market: Strong Healthcare System
7.4.3.1 French MS Drugs Market Forecast 2016-2026
7.4.4 UK MS Drugs Market
7.4.4.1 UK MS Drugs Market Forecast 2016-2026
7.4.5 Italian MS Drugs Market
7.4.5.1 Italian MS Drugs Market Forecast 2016-2026
7.4.6 Spanish MS Drugs Market
7.4.6.1 Spanish MS Drugs Market Forecast 2016-2026
7.5 Canadian MS Drugs Market: Country has Highest Rate of MS in the World
7.5.1 Canadian MS Drugs Market Forecast 2016-2026
7.6 Japanese MS Drugs Market Forecast 2016-2026
7.7 Chinese MS Drugs Market Forecast 2016-2026
7.8 Indian MS Drugs Market Forecast 2016-2026
8. Conclusions from Our Research and Analysis
8.1 How will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change?
8.3 How will National Markets Develop from 2016 to 2026?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：多発性硬化症治療薬の世界市場および研究開発展望2016-2026■ 英文：Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60619
■ 調査対象地域：グローバル
- 予知保全の世界市場：コンポーネント別、展開タイプ別、技術別、利害関係者別、業種別Predictive maintenance (PdM) is a process for monitoring equipment during operation with the purpose of identifying any deterioration, allowing maintenance to be planned, and reducing the operational costs. In this, data about previous breakdowns is used to model when failures are likely to occur and arbitrate at the same time as sensors detect the same conditions. PdM techniques are used to ident …
- サージ防護機器の世界市場2015-2019About Surge Protection Device Sudden increase in voltage significantly above the designated level in the flow of electricity is termed as power surge. These sudden spikes in the flow of electricity are harmful to appliances. It can damage machines after frequent surges or immediately. Surge suppressor devices protect electrical appliances from getting damaged by diverting the extra electricity gen …
- 血管内超音波検査（IVUS）の世界市場2016-2020About Intravascular Ultrasound Intravascular ultrasound (IVUS) is a catheter-based diagnostic device that uses sound waves to view the inside of a coronary artery by providing a real time view. IVUS is also called intravascular echocardiography as it is a combination of echocardiography and cardiac catheterization. Intravascular ultrasound device comprises a specially designed catheter with small …
- 食品・飲料倉庫保管の世界市場2017-2021ABSTRACTAbout Food and Beverage Warehousing F&B warehousing is an essential aspect of food supply chain because most foods and beverages are temperature sensitive and perishable. Refrigeration helps to keep products fresh and prevents contamination. The competitiveness of the industry is driven by service or infrastructure ability of vendors apart from price and value-added services offered. [Key …
- 無菌包装の世界市場2017-2021About Aseptic Packaging Aseptic packaging is the packaging of products in the aseptic environment in pre-sterilized containers, to prevent the products from contamination and maintain freshness for a long period of time. Aseptic packaging involves flash pasteurization of products to retain their original aroma, texture, and organoleptic characteristics and contains no preservatives or additives. T …
- ナイトビジョンデバイスの世界市場：カメラ、スコープ、ゴーグルIn this report, the global night vision device market has been broadly classified on the basis of device type, technology type, application, and geography. The major device types include night vision cameras, night vision goggles, and night vision scopes. The night vision camera segment is expected to be the fastest-growing segment in the overall market, projected to grow at the fastest CAGR of 11 …
- 微生物資材（有用微生物）の世界市場：植物成長促進資材、生物的防除資材、植物耐性スティミュラントThe agricultural inoculants market has grown exponentially in the last few years and this trend is projected to continue. The market was valued at $232.22 million in 2013; and projected to grow at a CAGR of 9.5% from 2014 to 2019, the market is projected to reach $398.56 million by 2019. The market is being driven by rise in the cost and demand for fertilizers globally and increasing awareness abo …
- 食品加工機械の世界市場2015-2022According to Stratistics MRC, the Food Processing Machinery Market accounted for $53.22 billion in 2015 and is expected to reach $92.51 billion by 2022 growing at a CAGR of 8.2% from 2015 to 2022. Increasing disposable incomes and growing awareness about processed food are the key factors fueling the market growth. The bakery processing held the largest share in terms of revenues during the foreca …
- 世界のNAND型フラッシュメモリ市場動向（2014-2018）About NAND Flash Memory NAND flash memory is a non-volatile storage technology that enables rapid read and write operations in memory cards. With respect to the design of NAND flash memory chips, the memory cells in these chips are connected in a series that resembles a NAND gate. The series connection consumes less space than a parallel connection, reducing the cost of NAND flash devices. This ma …
- 建設用重ダンプトラックの世界市場2017-2021ABSTRACTAbout Construction Dumper A construction dumper is defined as the medium used to transport loose materials such as sand, gravel, aggregates, and others for construction purposes. A construction dumper has an open bed box at the rear end of the dump truck; it has a hydraulic piston, which lifts the hauler or trailer to dump the required material onto the ground. A construction dumper is def …
- 世界のマンガン市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of manganese, covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing manganese production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s market overview covers the following: manganese p …
- 車両緊急通報システム（eCall）の世界市場2016-2020：標準取り付け、TPS取り付けAbout Automotive eCall eCall is an initiative by the transportation safety regulatory bodies to provide immediate assistance to people involved in accidents. It is a sub-system of telematics systems being installed in a vehicle. Implementation of eCall requires significant investment in infrastructure. In the case of a crash, it contacts the closest emergency center and forwards the GPS location o …
- 商業用水処理装置の世界市場2016-2020About Commercial Water Treatment Equipment The commercial water treatment equipment is used in schools, offices, hospitals, restaurants, hotels, construction sites, laboratories, and organizations. The stringent government regulations and growing health concerns are positively impacting the commercial water treatment market. In addition, increased construction activities that require water treatme …
- 米国のソフトドリンク市場About soft drinks The soft drinks market in the US comprises carbonated soft drinks, bottled water, juices and concentrates, RTD tea and coffee, and functional drinks. The consumption of soft drinks is driven by consumers across all ages owing to the indulgence and taste associated with the products. An increase in operational efficiency will drive the growth of the soft drinks market in the US du …
- 世界のセメント市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of cement, covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing cement production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s market overview covers the following: cement production …
